TODD STRATEGY GROUP for MYRIAD GENETIC LABORATORIES INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 19, 2018 | $40,000 | Replaced |
| 3rd Quarter - Termination | Nov 1, 2018 | $30,000 | Replaced |
| 3rd Quarter - Termination Amendment | Nov 5, 2018 | $30,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Medical/Disease Research/Clinical Labs MED
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | — |
| DANIEL M TODD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.